Abstract
Accurate classification and risk stratification is critical for clinical decision making in AML patients. In the newly proposed World Health Organization (WHO) and International Consensus classifications (ICC) of hematolymphoid neoplasms, the presence of myelodysplasia-related (MR) gene mutations is included as one of the diagnostic criteria of AML, myelodysplasia-related (AML-MR), largely based on the assumption that these mutations are specific for AML with an antecedent myelodysplastic syndrome. ICC also prioritizes MR gene mutations over ontogeny (as defined by clinical history). Furthermore, European LeukemiaNet (ELN) 2022 stratifies these MR gene mutations to the adverse-risk group. By thoroughly annotating a cohort of 344 newly diagnosed AML patients treated at Memorial Sloan Kettering Cancer Center (MSKCC), we show that ontogeny assignment based on database registry lacks accuracy. MR gene mutations are frequently seen in de novo AML. Among MR gene mutations, only EZH2 and SF3B1 were associated with an inferior outcome in a univariate analysis. In a multivariate analysis, AML ontogeny had independent prognostic values even after adjusting for age, treatment, allo-transplant and genomic classes or ELN risks. Ontogeny also stratified the outcome of AML with MR gene mutations. Finally, de novo AML with MR gene mutations did not show an adverse outcome. In summary, our study emphasizes the importance of accurate ontogeny designation in clinical studies, demonstrates the independent prognostic value of AML ontogeny and questions the current classification and risk stratification of AML with MR gene mutations.
Key points
Both ontogeny and genomics show independent prognostic values in AML.
The newly proposed myelodysplasia-related gene mutations are neither specific to AML-MRCWHO2016 nor predictive for adverse outcomes.
Ontogeny stratifies the outcome of AML with myelodysplasia-related gene mutations.
Competing Interest Statement
M.E.A served as consultant for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, and Roche; and has received honoraria from Biocartis, Invivoscribe, physician educational resources (PER), Peerview Institute for medical education, clinical care options, RMEI medical education. A.J.S. reports his spouse is an employee of Bristol-Myers Squibb. B.J.B served on the advisory board for Oncovalent and Bristol Myers Squibb. S.F.C. is a consultant for and holds equity interest in Imago Biosciences, none of which are directly related to the content of this paper. J.L.G. received consulting fees from GLG. M.B.G. receives research support from Actinium, Amgen, and Sanofi and has served in an advisory role for Sanofi, Novartis, and Allogene. R.K.R has received consulting Fees from Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Constellation/Morphosys, Sierra Oncology/GSK, Sumitomo Dainippon Kartos, Servier, Zentalis, Karyopharm and research funding from Constellation pharmaceuticals, Ryvu, Zentalis and Stemline Therapeutics. O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, Harmonic Discovery Inc., and Pfizer Boulder; O.A.-W. has received prior research funding from H3B Biomedicine, Nurix Therapeutics, Minovia Therapeutics, and LOXO Oncology unrelated to the current manuscript. A.D.G. received research funding from Celularity, ADC Therapeutics, Aprea, AROG, Pfizer, Prelude, and Trillium; received research funding from and served as a consultant for Aptose and Daiichi Sankyo; served as a consultant and member of advisory committees for Astellas, Celgene, and Genentech; received research funding from, served as a consultant for, and was a member of advisory committees for AbbVie; and received honoraria from Dava Oncology. M.S.T. has received research funding from AbbVie, Orsenix, BioSight, Glycomimetics, Rafael Pharmaceuticals and Amgen. M.S.T. is on the advisory boards of AbbVie, Daiichi-Sankyo, Orsenix, KAHR, Jazz Pharmaceuticals, Roche, BioSight, Novartis, Innate Pharmaceuticals, Kura, Syros Pharmaceuticals and Ipsen Biopharmaceuticals. M.S.T. has received royalties from UpToDate. M.S.T. is on DSMB of HOVON protocol Ho156 and adjudication committee of Foghorn protocol FHD-286. RLL is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics and Isoplexis for which he receives equity support. RLL receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys and Novartis. He has received honoraria from Astra Zeneca and Kura for invited lectures and from Gilead for grant reviews. E.P is a founder, equity holder and holds fiduciary role in Isabl Inc. M.R. is on the scientific advisory board in Auron Pharmaceutical for which he received equity support. He receives research funding from Celularity, Roche-Genentech, Beat AML and NGM and travel fund from BD Biosciences. W.X. has received research support from Stemline Therapeutics.
Funding Statement
This study was funded by the Center for Hematologic Malignancies at MSKCC and in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. A.J.S. is supported by a Young Investigator Award from the Edward P. Evans Foundation. A.J.D. is a William Raveis Charitable Fund Physician-Scientist of the Damon Runyon Cancer Research Foundation (PST- 24-19). S.F.C. is supported by a National Cancer Institute grant (K08 CA241371-01A1). J.L.G. is supported by a National Cancer Institute grant (NCI K08CA230172) and Equinox Cycle for Survival. O.A.-W. is supported in part by the Edward P. Evans Foundation, NIH/NCI (R01 CA251138 and R01 CA242020), NIH/NHLBI (R01 HL128239), NIH/NCI P50 CA254838-01, and the Leukemia & Lymphoma Society. R.L.L. is supported by a Cycle For Survival Innovation Grant and National Cancer Institute R35 CA197594. WX is supported by Alex Lemonade Stand Foundation and the Runx1 Research Program, Cycle for Survival Equinox Innovation Award in Rare Cancers, MSK Leukemia SPORE Career Enhancement Program and a National Cancer Institute grant (K08CA267058-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Institutional Review Board at the memorial sloan kettering cancer center had approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- WHO
- World Health Organization
- ICC
- International Consensus Classification
- ELN
- European LeukemiaNet
- AML-MRC
- Acute myeloid leukemia with myelodysplasia-related changes
- t-AML
- therapy-related acute myeloid leukemia
- MDS
- myelodysplastic syndromes
- MDS/MPN
- myelodysplastic/myeloproliferative syndromes
- MR-Hx
- acute myeloid leukemia, myelodysplasia-related based on history of MDS or MDS/MPN
- MR-CG
- acute myeloid leukemia, myelodysplasia-related based on MDS-defining cytogenetic changes (no history of MDS or MDS/MPN)
